<DOC>
	<DOCNO>NCT02892812</DOCNO>
	<brief_summary>The purpose study evaluate safety immunogenicity LBVE013 ( Pneumococcal 13-valent conjugate vaccine [ diphtheria CRM197 protein ] ) LBVE014 ( Pneumococcal 14-valent conjugate vaccine [ diphtheria CRM197 protein ] ) healthy adult .</brief_summary>
	<brief_title>A Phase I Clinical Trial 13-valent Pneumococcal Conjugate Vaccine 14-valent Pneumococcal Conjugate Vaccine Adults</brief_title>
	<detailed_description />
	<mesh_term>Pneumococcal Infections</mesh_term>
	<mesh_term>Vaccines</mesh_term>
	<mesh_term>Heptavalent Pneumococcal Conjugate Vaccine</mesh_term>
	<criteria>Healthy adult old 19 year old young 50 year old A subject inform purpose , method , efficacy clinical study sign write informed consent form A subject participate clinical study within 3 month screen A subject vaccinate vaccine within 4 week screening , expect receive vaccination clinical study period A subject medical history hypersensitive reaction ( e.g . anaphylaxis ) test drug ingredients A subject receive immunoglobulin bloodderived material within 3 month screen A subject immunologic function disorder include congenital acquire immunodeficiency disorder A subject receive immunosuppressive therapy drug affect immunological reaction A subject pyrexia 38 Celsius degree day vaccination investigational product A subject medical history Invasive Pneumococcal Disease ( IPD ) pneumonia cause Streptococcus pneumoniae A subject vaccinated pneumococcal vaccine screen A subject receive vaccine contain diphtheria toxoid within 6 month screen ( e.g . adult Td vaccine )</criteria>
	<gender>All</gender>
	<minimum_age>19 Years</minimum_age>
	<maximum_age>50 Years</maximum_age>
	<verification_date>September 2016</verification_date>
</DOC>